Aging leads to DNA methylation alterations associated with loss of lineage fidelity and breast cancer in mammary luminal epithelial cells

Parijat Senapati[1], Masaru Miyano[2], Rosalyn W. Sayaman[2,4], Mudaser Basam[1,2], Candi Trac[1], Amy Leung[1], Mark A. LaBarge[2,3], Dustin E. Schones*[1,3]

[1]Department of Diabetes Complications and Metabolism, Beckman Research Institute, City of Hope, Duarte, CA, 91010, USA

[2]Department of Population Sciences, Beckman Research Institute, City of Hope, Duarte, CA, 91010, USA

[3]Irell & Manella Graduate School of Biological Sciences, City of Hope, Duarte, CA, USA

[4]Department of Laboratory Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA

*Corresponding Author:

Dustin E. Schones, Ph.D.

Department of Diabetes Complications and Metabolism

City of Hope

Duarte, CA, 91010

Email: dschones@coh.org

Phone: 626-218-1319

Abstract

DNA methylation in mammalian genomes is critical for repression of transposable elements (TEs) and regulation of transcription factor (TF) binding. Methylation loss in cancer cells results in widespread TE activation and altered TF binding that subsequently impact transcriptional networks. While the aging process is similarly characterized by changes to the methylome, the extent and its functional consequences have remained unclear. We report here that aging leads to distinct methylation changes in luminal epithelial cells, a key cell lineage implicated in age-related breast cancers. Regulatory elements and evolutionarily old TEs display consistent methylation changes at lineage-specific TF binding sites. Evolutionarily younger TEs, however, exhibit stochastic methylation loss that corresponds with increased methylation entropy. Each of these classes of methylation change impact the regulation of genes associated with luminal breast cancer. Altogether, our results indicate that aging leads to distinct DNA methylation changes that can rewire gene networks important for breast cancer.

Keywords: transposable elements, aging, DNA methylation, human mammary epithelial cells, luminal epithelial cells, breast cancer

Background

Aging is associated with a progressive decline of tissue and organ functions and is a significant risk factor for many diseases, including cancer. At the genomic level, alterations to the epigenome may contribute to the development of age-associated diseases [1,2]. DNA methylation is a relatively stable component of the epigenome that gets established in early development and is maintained through successive cell division cycles to preserve cell identity [3]. It is now well-established, however, that DNA methylation patterns are altered with age [4-7]. DNA methylome comparisons of human CD4[+] T cells from a newborn and a centenarian suggested an overall decrease in methylation levels with age [7]. Moreover, DNA methylation levels of specific CpG sites show a significant correlation with age across diverse tissues [5]. This set of CpG dinucleotides, known as an 'epigenetic clock', can predict the chronological age of cells based on DNA methylation patterns [5]. It is clear that DNA methylation changes to specific CpG sites occur with aging, whereas the causes of these alterations and their impact on disease risk and progression are not well understood.

Over 75% of breast cancer diagnoses are in women over the age of 50 [8], and 80% of those age-related cancers are of the luminal subtype [9]. Aging in breast tissue is accompanied by increases in estrogen receptor expression [10], and significant physiological changes such as an increase in fat content and a decrease in connective tissue [11] that alter the microenvironment of the mammary epithelium. Previous studies have suggested a complex interplay between the various epithelial cell types and microenvironment that leads to changes in molecular properties and the proportion of cell populations [12,13]. Luminal epithelial cells (LEps) and myoepithelial cells (MEps) are the two principal lineages in breast epithelia. Striking age-dependent changes in abundance and phenotype occur among LEps [12,14-16], which are the chief suspect cell of origin for luminal cancer subtypes [17]. Furthermore, aging-associated tissue microenvironment changes contribute to epigenetic and transcriptional changes in the mammary epithelium [18].

In vitro, transformed human mammary epithelial cells (HMECs) from older

postmenopausal women (> 55 y) exhibit gene expression patterns characteristic of luminal

breast cancer subtypes. In contrast, transformed HMECs from younger premenopausal women

(< 30 y) show more properties of basal breast cancers [19]. This suggests that cells from older

women may harbor age-related epigenetic states that predispose them to develop luminal-

subtype breast cancers. Intriguingly, LEps from older women express signaling molecules

consistent with those of immortalized luminal cells, suggesting that age-associated changes can

elevate cancer risk [14]. Epigenetic clock studies in breast tissue have indicated that women with

luminal breast cancers exhibit increased epigenetic age even in the adjacent normal breast

tissue [20]. Although earlier studies have investigated the role of epigenetic changes in breast

tissue with age and its potential role in elevating breast cancer risk [20,21], these studies were

either performed in bulk mammary tissue or interrogated a small subset of CpG sites in the

genome. Therefore, a complete understanding of age-associated DNA methylation changes in

specific human mammary cell types is still lacking.

Repetitive elements derived from transposable elements (TEs) constitute ~50% of the

human genome and are classified based on their method of transposition [22]. While some

elements, such as Alu, LINE, and SVA elements, have maintained retrotransposition

competence [23], most elements have accumulated enough mutations to lose their ability to

propagate [24]. They can still, however, carry latent regulatory potential [24]. Cancer cells with

genome-wide loss of DNA methylation frequently exhibit activation of transposable elements

[25,26]. Increased expression of retrotransposons and active retrotransposition have been

observed in aging mouse tissues [27,28], and LINE-1 expression is increased during fibroblast

replicative senescence, a form of cellular aging [29]. We, therefore, reasoned that aging would

lead to the loss of epigenetic silencing of transposons.

To evaluate the impact of aging on TEs we profiled global DNA methylation levels using WGBS in non-senescent human mammary luminal epithelial cells from young and old women. We found that the chronological age of human mammary luminal epithelial cells was associated with DNA methylation changes at regulatory elements and loss of methylation at evolutionarily young transposable elements. Methylation changes at regulatory elements are driven by altered expression and activity of lineage-specific transcription factors such as ELF5 and TP63. Recently evolved TEs mainly lose methylation in a stochastic manner and exhibit increased methylation disorder, presumably due to loss of fidelity of maintenance methylation [30]. TEs that lose methylation with age were also hypomethylated in breast cancers. Loss of suppression of TEs leads to their cryptic expression in pre-breast cancer tissues (DCIS). Furthermore, they function as regulatory elements in breast cancer influencing increased expression of genes associated with luminal-subtype breast cancers. Overall, our results suggest that CpG-dense TEs lose silencing with age and can function as regulatory elements that lead to expression of key deleterious genes during breast cancer development.

Results

Aging leads to altered DNA methylation patterns in mammary luminal epithelial cells.

To investigate the genome-wide changes in DNA methylation associated with aging in the mammary tissue, we performed whole-genome bisulfite sequencing (WGBS-seq) on human mammary LEps from five younger (<30y) and five older (>55y) women (**Figure S1A**). We isolated LEps from 4th passage (p4) cultures of pre-stasis finite-lifespan HMECs from normal reduction mammoplasty (RM) tissues [12]. These pre-stasis LEps from primary cultures maintain gene expression and DNA methylation profiles that mirror those in tissue [16,18]. Moreover, these are non-senescent cells and therefore are a valuable resource that can be used to interrogate

aging-dependent changes in the breast tissue – distinct from those arising from cellular senescence.

We sequenced all ten WGBS libraries to ~30X genome coverage, generating ~ 1B 150-bp paired-end reads (~86 Gb uniquely mapped sequence per sample) (Table S1) and obtained a representation of about 95% of individual CpG sites in our samples (see Methods and Tables S1, S2). To obtain a global view of aging-dependent changes to the methylome, we compared the WGBS profiles of young and old individuals. We did not observe any changes in the global methylation levels across the genome with age (**Figure S1B, C**). However, principal component analysis (PCA) of the WGBS data separated the old and the young samples on the first principal component axes (16.9% cumulative variance; **Figure S1D**) indicating that there are differences in the methylomes that are not apparent on a genome-scale. Pairwise comparison of CpG methylation of all ten samples (45 combinations) at various genomic features showed that methylation at CpG islands, promoters and exons are highly correlated among samples (**Figure S1E**). However, methylation levels at repeat regions, especially at SVA elements and SINE elements were the least correlated, indicating high methylation variability at these sites (**Figure S1E**). As mapping to repetitive regions can be challenging, we assessed mappability and coverage at repetitive regions. We found no systematic biases, suggesting these results are not due to technical artifacts from mapping (**Fig S1F-G**).

To identify genome-wide age-associated changes to DNA methylation, we found all differentially methylated regions (DMRs) (see Methods) in old LEps as compared to the young LEps. We identified 18,860 age dependent DMRs, with 7,207 showing methylation loss and 11,653 showing methylation gain in old LEps (**Figure 1A**). Most DMRs were 100-500bp in length (**Figure S1H**). The methylation changes at DMRs were confirmed with heatmaps showing methylation levels across samples (**Figure 1A**), as well as kernel smoothed methylation plots of representative DMRs (**Figure 1B**). DNA methylation changes were observed at all common

genomic features including in introns (53%), gene promoters (10%), CpG islands (3%) and intergenic regions (45%) (**Figure S1I-J**). These results suggest that specific loci, including repeat elements and CpG islands undergo methylation changes in LEps in response to aging. We identified genes with methylation changes at promoter regions and performed gene set enrichment analysis (GSEA) to identify pathways associated with aging in LEps. Genes with methylation loss in old LEps were enriched in gene sets expressed in mammary stem cells, epithelial-to-mesenchymal transition, apical junction and genes downregulated in luminal breast cancer (**Figure S2A**). Genes that gained methylation at promoters were enriched in Polycomb target genes in embryonic stem cells and luminal genes that are downregulated in mammary stem cells and basal breast cancer but upregulated in luminal breast cancer (**Figure S2B**). Age-dependent increase in DNA methylation of Polycomb (PRC2) target gene promoters has been observed in other tissues and model systems [4,31-34]. Moreover, EZH2, a component of the PRC2 complex is important for maintaining the mammary luminal progenitor population [35,36]. These results indicate aging induces DNA methylation changes at genes specific to mammary epithelial lineages and luminal subtype breast cancers.

Transposable elements contribute transcription factor binding sites [36] and can function as regulatory elements even in normal tissue [37,38]. We identified the repeat elements that overlap DMRs and determined if any TE subfamilies were enriched at these regions. We found that LTR subfamilies, HERVH, MER52A, MER52D and LTR27E were enriched at DMRs with methylation loss in old LEps (**Figure 1C**). HERVH elements have been shown to function as enhancers, regulate long non-coding RNAs, and are important for the maintenance of pluripotency [39]. MER52A and MER52D elements function as enhancers in other cell types [40,41] indicating these could function as enhancers in old LEps. Centromeric gamma satellite repeat (GSAT) and human satellite 4 (HSAT4) were also enriched at regions of methylation loss (**Figure 1C**). DNA methylation loss at these elements was accompanied by an increase in chromatin accessibility

in old LEps (**Figure 1D, S2E and F**). Decondensation of pericentromeric heterochromatin is a

characteristic feature of senescent cells [42] and centromere dysfunction has been reported with

age [43]; however, methylation changes in centromeric DNA in aging cells has not been studied.

DMRs with methylation gain showed enrichment of LTR subfamilies LTR10C, HERVE, and

MER11D (**Figure S2C**), which were less methylated than expected in the younger cells,

suggesting they have been co-opted in LEps (**Figure S2D**). MER11D elements have previously

been shown to be hypomethylated in breast tissue and function as tissue-specific enhancers [37].

Aging-associated DNA methylation changes occur at lineage-specific transcription factor

binding sites

To investigate whether DNA methylation changes were associated with transcription

factor (TF) binding signatures, we performed motif enrichment analysis using position weight

matrices (PWMs) from the JASPAR database [44]. DMRs that lose methylation are enriched for

binding sites of TFs such as EGR1, TP63, TP73, TEAD1, TEAD4, and RUNX1 (**Figure 2A left**

panel). TEs with methylation loss also showed enrichment of similar transcription factor binding

sites, including TEAD1-4, TP63, TP73, and EGR1 (**Figure 2B left panel**). NFI half binding sites

were enriched in regions with loss as well as gain of methylation. NFI half-sites can be bound

by NFI family TFs NFIA, NFIC, and NFIX. TEAD, TP63, TP73, NFI, and EGR1 sites have been

previously shown to be enriched in active regulatory elements in basal/myoepithelial cells [45]. To

investigate whether these TFs change expression with age, we checked their expression using

RNA-sequencing data in young versus old LEps, and in LEps versus MEps [16]. *TP63* and *NFIA*

showed increased expression in old compared to young LEps (**Figure 2C and S3A**). Although

not all TFs showed an increase in expression with age, we did note that *TP63, NFIA, EGR1, and*

TP73 have relatively higher expression in MEps as compared to LEps (**Figure 2A-B right panel**

and S3D). The expression patterns of TFs and the hypomethylation of their targets are

concordant with the known roles of these TFs. For example, young LEps do not express *TP63*, which is a MEp lineage-specific transcription factor [18]. Furthermore, TEAD1 and TEAD4 are DNA binding partners for YAP (Yes-associated protein), a transcriptional co-activator regulated by the Hippo signaling pathway. YAP is sequestered in the cytoplasm through activity of kinases downstream of the Hippo pathway [46]. Old LEps exhibit increased expression of *TP63* as well as increased nuclear YAP localization [13,18], and thereby increased YAP activity and TEAD binding. YAP is also known to bind TP73 and RUNX2 [46]. These results suggest that increased expression/activity of myoepithelial-specific TFs in old LEps could lead to increased binding and loss of DNA methylation in these regions (**Figure S3E**).

Conversely, DMRs with methylation gain are enriched for binding sites of the ETS family of transcription factors EHF, ELF3, ELF5, ELF4, ETV1, ETS1, ETV4, GABPA, and NFI half and full sites (**Figure 2D left panel**). TEs that gain methylation also showed enrichment of similar TF binding sites in addition to the SOX family of TFs (**Figure 2E, left panel**). ELF5 is a luminal lineage-specific transcription factor that exhibits decreased expression with age (**Figure 2F**) [18]. Besides *ELF5*, transcription factors *EHF* and *ELF3* show relatively higher expression in LEps as compared to MEps (**Figure 2D and E right panel and 3D**). Expression of *SOX4* decreases, whereas *SOX15* increases with age in LEps (**Figure S3B-C**), indicating loss of expression of luminal lineage-specific TFs and increased expression of myoepithelial-specific TFs (**Figure S3D**). These results further suggest that decreased expression of luminal lineage-specific TFs may lead to a decrease in binding and protection of binding sites from DNA methyltransferases (DNMTs). This, in turn, may result in the methylation and repression of these luminal lineage-specific regions (**Figure S3E**). Generally, sites of methylation loss were enriched for myoepithelial-specific TF binding motifs (**Figure 2G**), whereas sites of methylation gain were enriched for luminal lineage-specific TF binding motifs (**Figure 2G**). Collectively, these results

suggest that aging-associated DNA methylation changes in LEps are orchestrated by lineage-

specific transcription factors.

Next, we determined which TE subfamilies contribute TF binding sites to the differentially

methylated regions (DMRs). Among the TEs that lose methylation, HERVH elements showed

the highest enrichment for TEAD and RUNX TF binding sites (**Figure 2H**). TP63 binding sites

were enriched at AluSx, AluSp, L2, and L3 elements. TP63 (p63) belongs to the p53 family of

TFs that includes TP53 (p53) and TP73 (p73). p53 binding sites occur in Alu elements and other

retrotransposons through deamination of a methylated CpG site [47,48]. p53 can repress

transposons through direct binding at these sites [49]. Since p63 and p73 share similar binding

sites as p53, it is possible that in mammary epithelial cells, these sites are repurposed as

regulatory elements through p63 binding. ETS family TF binding sites that gain methylation were

enriched in MIRb, MIR subfamilies of SINE elements and L2, L2a-c LINE subfamilies (**Figure

S3E**). SOX family TF binding sites were contributed by AluY, LTR10 and MER11D elements

(**Figure S3E**). Together, these results suggest that TEs have been co-opted by lineage-specific

TF binding sites and contribute to aging-dependent DNA methylation changes in LEps.

Luminal lineage-specific regulatory elements gain methylation, whereas myoepithelial

regulatory elements lose methylation with age.

Given that aging-associated DNA methylation changes occurred at sites containing

lineage-specific TF binding sites, we examined the functional relevance of these DMR regions

in the breast tissue. We predicted chromatin states at the DMRs using published histone

modification ChIP-seq datasets performed in mammary epithelial lineages [45]. To discern whether

DMRs reflect changes in cell properties, we predicted chromatin states in mature luminal, luminal

progenitor, and basal (MEp) cells from RM tissue of a young (19y old) donor [45]. We classified

DMRs into seven chromatin states in each cell type based on the extent of overlap with each

state (see Methods; **Figure S4A-C**). DMRs with methylation loss in old LEps overlap primarily

with MEp-specific promoter and enhancer regions, accounting for about 80% of all DMRs

(**Figure S4D**) and 74% of DMRs containing TEs (**Figure S4E**). As these sites also contain

binding sites for TFs enriched at MEp-specific active enhancers [45], these results indicate that

MEp-specific regulatory elements lose methylation in old LEps. Active enhancer sites are

hypomethylated [50,51] and methylation loss at MEp-specific regulatory elements might indicate an

epigenetic shift towards MEp gene expression patterns in LEps with age. Indeed, we do observe

an increase in expression of MEp genes in old luminal cells (**Figure S2A**) [16]. These data are in

line with previous studies suggesting that aging luminal cells acquire basal-like gene expression

signatures [12,13]. As regulatory elements such as promoters and enhancers are characterized by

accessible chromatin, we compared sites of chromatin accessibility using ATAC-seq in young

and old LEps to study changes in chromatin accessibility at DMRs. We found that open

chromatin peaks overlapping DMRs that lose methylation in the older LEps showed

corresponding increased accessibility in older LEps (**Figure S4F, J**). This result indicates loss

of methylation is associated with an increase in chromatin accessibility, consistent with these

sites containing regulatory elements [52].

Conversely, DMRs that gain methylation and overlap with putative promoter and

enhancer regions in luminal progenitor cells account for about 42% of all DMRs (**Figure S4G**)

and 43% of DMRs containing TEs (**Figure S4H**). Of note, our strategy of FACS enrichment of

luminal cells using PROM1 (CD133) positive and NGFR (CD271) negative cells (**Figure S1A**)

includes luminal progenitor cells [53]. As these DMR sites also contain binding sites for TFs

enriched at luminal lineage-specific active enhancers, these results indicate that luminal

progenitor-specific regulatory regions gain DNA methylation in aging LEps. Furthermore, open

chromatin peaks overlapping DMRs with methylation gain showed a decrease in chromatin

accessibility, suggesting repression of these regulatory elements (**Figure S4I, K**). Together,

these results suggest that aging LEps acquire permissive chromatin states at MEp-specific regions and repress luminal progenitor-specific chromatin regions through changes in DNA methylation. TEs with lineage-specific TF binding sites contribute to aging-dependent DNA methylation changes at regulatory regions.

Aging leads to methylation loss at young transposable elements.

Aging is associated with increased transcriptional variability, cell-to-cell heterogeneity, and DNA methylation variability [54-57]. Given that DNA methylation is an important mechanism for silencing of evolutionarily young TEs [58], we asked whether increased variability in DNA methylation with age leads to loss of methylation at young TEs. Since some amount of DNA methylation variability is expected in human populations, we first identified regions of variable methylation across all 10 individuals using the Systematic Interindividual Variation (SIV) approach [59] (see Methods). We identified 23,921 regions that were variably methylated only in old samples and 25,585 regions that were specific to the young samples (**Figure S5A**). Regions variably methylated in old samples mainly showed methylation loss (17,780 of 23,921; 74.3%) with some regions gaining methylation (6,141 of 23,921; 25.67%). The variable regions usually were 150bp-450bp in length with some spanning 2-2.5kbs (**Figure S5B and S5C**). We next examined whether variable regions contained TEs and found that 68.7% of regions variable in young and 71.4% regions variable in old overlapped with TEs (**Figure S5D**). Among the TEs that are variably methylated in old, about 76.9% lose methylation and 23.13% gain methylation (**Figure S5E**).

We further investigated the characteristics of TEs that are variably methylated in old. The evolutionarily younger elements (<100 million years) [60] tended towards DNA methylation loss, whereas the older TE elements (>100 million years) tended to gain methylation in old cells

(**Figure S6A and Figure 3A)**. As some TE subfamilies, especially Alu elements, are much more

abundant than others, we determined the specific TE subfamilies that are enriched at these

regions using random controls. SINE elements were most abundant at variably methylated

regions and young SINEs showed variable methylation loss whereas older SINE elements

showed variable methylation gain in old LEps (**Figure 3B**). LINE elements with variable

methylation loss were younger than those that gained methylation (**Figure 3C**). Young LTR/ERV

elements showed methylation loss and gain (**Figure 3D**), indicating possible exaptation of these

elements in LEps. These results indicate that evolutionarily young TEs that are likely to be

regulated by DNA methylation can lose methylation with age and that this process could be

variable among individuals.

We further inspected the specific subfamilies enriched at the variably methylated regions.

While young Alu elements such as AluY and AluS are highly abundant in the genome, a few

AluS subfamilies were slightly enriched among the variably methylated regions (**Figure 3E**). The

TE subfamilies enriched at these regions were AluSq2, L1PA(2-6), HERVH, AluSg4, AluYc,

L1P1, L1P2, and MER11A elements (**Figure 3E**). HERVH elements are particularly interesting

as they were enriched at DMRs as well as variable regions of methylation loss (**Figure 1F and**

3E-F).

Aging leads to stochastic methylation loss at transposable elements associated with

heterochromatin regions.

We next examined the possible mechanisms of increased methylation variability at TEs

with age. Errors in maintenance methylation during replication has been proposed to be involved

in aging-dependent stochastic methylation changes [61]. Methylation loss in cancer cells occurs

at late replicating regions associated with heterochromatin due to inefficient maintenance

methylation by DNMT1 [62]. We therefore tested whether variably methylated regions are

associated with replication timing and heterochromatin. Given that replication time is known to be conserved in normal and cancer cell lines [63], we utilized Repli-Seq data from MCF7 cells available through the ENCODE project. We found that a higher proportion of variably methylated regions in older LEps were at late replicating regions compared to variably methylated regions in younger samples (**Figure 4A-B**). Similarly, more variably methylated TEs in older samples were at late replicating regions as compared to those in younger samples (**Figure 4C-D**). We also used Hi-C data from MCF10A cells to determine the A and B-type compartments in mammary epithelial cells [64] that are associated with euchromatin and heterochromatin respectively. A higher proportion of variably methylated regions in older samples (54.3%) were in B-type compartments as compared to 47.7% in young (**Figure 4E, top panel**). Variably methylated TEs in old also had a higher proportion (55.1%) in B-type compartments as compared to 49.5% in young (**Figure 4E, bottom panel**). Among the variably methylated TEs with methylation loss, we identified several TE subfamilies that had a higher proportion (> 55.1 %) of variably methylated copies in the B-compartment (**Figure S6B**) indicating their enrichment at heterochromatin regions.

Since impaired DNA methylation maintenance at heterochromatin regions could lead to discordant methylation patterns among adjacent CpGs, we examined whether there is an increase in intra-sample methylation heterogeneity at variably methylated TEs in older individuals. For this, we calculated methylation entropy, a measure of methylation heterogeneity between adjacent CpGs, for 150 bp non-overlapping windows across the genome [65]. Variably methylated regions identified in old individuals had a higher methylation entropy in B-type compartments (**Figure 4F**). Similarly, variably methylated TEs in old individuals showed higher methylation entropy in B-type compartments (**Figure 4G**). Variably methylated TEs in old showed an increase in methylation heterogeneity in old samples as compared to young (**Figure S6C and D**). We further examined whether increase in entropy was associated with methylation

loss at the variably methylated TEs enriched at B-type compartments. We found that indeed

variably methylated HERVH and MER52A loci showed methylation loss accompanied by

increase in entropy (**Figure 4H and I**). Together, these results indicate that evolutionarily young

CpG dense TEs exhibit stochastic loss of methylation with age.

Transposable elements with age-dependent methylation loss are activated in breast

cancer.

TEs have latent regulatory potential and, when not repressed, can function as regulatory

elements. Given our observations that evolutionarily young, CpG dense transposons lose

methylation stochastically with age, we examined whether breast tumors show loss of epigenetic

suppression at these elements. We utilized a published dataset of 30 breast cancer methylomes

[66] to examine whether TEs that lose methylation with age are hypomethylated in breast cancer

and whether lack of methylation at these elements is also variable in breast cancer. Variable

DNA methylation loss at heterochromatic regions leads to formation of partially methylated

domains (PMDs) in breast cancer that are hyper-variable among individuals [66]. We therefore

reasoned that TEs at heterochromatin regions that exhibit variable methylation loss would be

enriched at PMDs in breast cancer.

For each copy in a TE subfamily, we examined the number of breast tumors in which it

overlapped with a PMD. The number of breast tumors (of 30) that contained a variably

methylated TE at a PMD was denoted as PMD frequency. There was a large variation in the

PMD frequency at variably methylated TEs (**Figure 5A**). However, MER52A, L1P1, L1PA3,

L1PA4 and HERVH elements were more likely to be at PMDs in multiple breast cancer samples

(**Figure 5A**). Loss of TE suppression leads to cryptic transcription and alternative isoforms due

to splicing with neighboring genes in cancer cells [67]. In order to investigate the potential of this

happening in breast cancer, we examined published RNA-seq data from high-grade Ductal

carcinoma in situ (DCIS) [68]. DCIS is considered to be a form of pre-breast cancer. We used the

SQuIRE pipeline [69] to measure gene and TE expression changes in DCIS as compared to

normal tissues. We found 197 age-hypomethylated TEs that showed higher expression in DCIS.

HERVH elements and L1PA2 elements were most common among the TEs that showed cryptic

transcription. A representative example of a HERVH element that loses methylation in aging

LEps and breast tumors is shown (**Figure 5B**). Cryptic transcription from this HERVH element

was observed only in DCIS samples (**Figure 5B**). We also found examples of exonization of

TEs; a MIRb into a non-coding RNA LOC1558357 expressed in DCIS (**Figure S7A**). While

aberrant expression of age hypomethylated TEs in DCIS was clear, we did not observe any

subtype specificity in the expression of these TEs.

Next, we determined whether these TEs with methylation loss function as regulatory

elements in breast cancer. To this end we utilized ATAC-seq data from The Cancer Genome

Atlas (TCGA) breast cancer cohort (TCGA-BRCA) and published ChIP-seq datasets from breast

cancer cell lines [70]. We identified 1197 TCGA-BRCA ATAC-seq peaks that overlap TEs with

methylation loss in aging LEps (**Figure 5C**). The L1PA2 LINE subfamily was highly represented

in the ATAC-seq dataset. Most of the TEs had open chromatin sites across luminal tumors

especially in lobular carcinomas (**Figure 5C**). Some TEs were accessible in basal subtype

tumors as well. These results indicate that TEs hypomethylated with age could function as

regulatory elements in breast cancer. To further verify these results, we identified chromatin

states at hypomethylated L1PA2 elements from ChIP-seq data available from breast cancer cell

lines [70]. L1PA2 elements exist in a bivalent promoter state in luminal (3 of 4) and HER2-positive

(2 of 3) cell lines (**Figure 5D**), with the presence of both H3K4me3 and H3K9me3 marks (**Figure

5D and Figure 7B**). Since, H3K4me3 and H3K9me3 marks are mutually exclusive, they might

be occupying the same sites in different cells. These results indicate that some cancer cells that

lose repression at TEs from DNA methylation and H3K9me3 can utilize these elements as

regulatory regions to rewire transcriptomes.

To determine whether loss of methylation at TEs can lead to changes in expression of

genes important in breast cancer, we mapped variably methylated TEs to genes within 50kb and

checked their expression in DCIS samples [68] and across TCGA datasets. A representative

example of a variably methylated HERVH element upstream of *CYB5A* gene is shown (**Figure**

5E). We found increased expression of *CYB5A* gene in DCIS samples (**Figure 5F**) and is highly

expressed in luminal breast tumors (Luminal A and Luminal B) as compared to basal tumors

(**Figure 5G**). These results indicate that TEs hypomethylated with age can regulate the

expression of genes important for luminal breast cancer and thereby support transformation.

Discussion

We report a comprehensive WGBS analysis of the aging-associated DNA methylation

alterations in normal human mammary luminal epithelial cells. Previous studies were done using

array-based technologies that cover only a fraction of the CpG sites in the genome [16,18,20,21].

Repeat elements are under-represented among the arrayed probes [71], making interpretation of

DNA methylation at repetitive regions difficult. Moreover, earlier DNA methylation studies were

performed using composite tissues that represented a mixture of cells [20,21]. We and others

showed that different cell lineages have unique responses to aging, and this is dependent on

cell-cell interactions and microenvironment changes [18,72]. For example, aging leads to cell

composition changes in blood cells where older individuals show a skew towards myeloid

lineages [73]. Changes in cell composition can confound the interpretation of DNA methylation

levels in bulk tissues. Thus, it is imperative to study age-dependent molecular changes in purified

cell populations.

Previous DNA methylome studies in human cells have suggested a global loss of methylation with age [7,65,74]. These studies were performed using CD4[+] T cells from a neonate and a centenarian [7], and sorted CD4[+] T cells [65] and skin keratinocytes [74] from young (<25 y) and old (>70 y) individuals. The global methylation loss with age was accompanied by a global increase in entropy or methylation discordance with age [65]. We did not observe a global methylation loss or a global increase in entropy in mammary luminal epithelial cells with age. This could be due to higher fidelity of DNA methylation maintenance in luminal cells or due to a smaller separation between the age of young (<30 years) and old (> 55 years) individuals in our study. This observation is supported by DNA methylome studies in aging mouse livers, where no global loss of methylation was observed, although specific changes at regulatory elements were detected [75]. Whereas no global methylation loss was detected, we did, however, find methylation changes at regulatory elements and variable methylation changes at young transposons.

DNA methylation is an important mechanism for silencing of transposable elements. Reactivation of transposable elements has been shown in cancer cells with global loss of DNA methylation [25,26]. While previous research comparing DNA methylation levels between a neonate and a centenarian reported that 12% of DMRs that lost methylation with age were located on Alu elements [7], changes in epigenetic silencing at TEs with aging has not previously been systematically investigated. Increased expression of retrotransposons and active retrotransposition have been reported in aging mouse tissues using bulk quantitative strategies [27,28], and, increased LINE-1 expression has been reported in senescent human fibroblasts *in vitro* [29]. However, the impacts of altered DNA methylation patterning and TE derepression on gene regulation in these systems was not investigated. We examined the impact of aging on DNA methylation at TEs using non-senescent mammary epithelial cells. We show that the evolutionary age of TEs is important for determining the response to aging. As older TEs can be

exapted and function as tissue-specific regulatory elements [24], aging-associated changes can

be attributed to cell-type-specific transcription factor activity. However, young CpG-dense

transposons are more likely to be silenced by DNA methylation and presumably lose methylation

by inefficient maintenance methylation by DNMT1. We indeed find that transposons with variable

methylation loss occur in late replicating regions associated with heterochromatin. This

observation is relevant in the context of proliferative capacity of breast epithelial cells. LEps have

significantly shorter telomere lengths as compared to isogenic MEps indicating that they are

among the most proliferative cells in breast epithelia [76,77]. Cancer cells are highly proliferative

and lose methylation at heterochromatin loci by a similar mechanism [62]. Taken together, it is

tempting to speculate that the LEp lineage is particularly susceptible to DNA methylation loss at

young TEs in addition to the loss of lineage fidelity in the aging breast tissue.

We further show that methylation loss at TEs with age is recapitulated in luminal breast

cancer. The derepressed TEs could lead to cryptic transcription or function as regulatory

elements in breast cancer cells. We also showed that TEs that lose silencing with age are

present as bivalent promoter loci in breast cancer cell lines, indicating loss of repression in

heterogenous populations of cells as opposed to being tightly regulated and completely silent in

normal cells. In addition, we showed that hypomethylated TEs could potentially regulate genes

associated with the luminal subtype of breast cancer. Altogether, these observations provide

further support to the observation that epigenetic changes with age could determine

susceptibility towards breast cancer. Retrotransposon activation has been widely observed in

nearly every human cancer, including breast cancer [78,79], and even in premalignant lesions [26].

This suggests that early events in tumorigenesis maybe driven by retrotransposon activity. We

show here, for the first time, that loss of transposon silencing is evident in aging luminal epithelial

cells that could predispose towards breast cancer. Future studies are needed to study the role

of these TEs in the early events of mammary cancer initiation.

Materials and Methods

Isolation of mammary luminal epithelial cells

Primary non-immortalized HMECs were generated and maintained, as described previously [80].
HMEC strains were established in the laboratory of Dr. Martha Stampfer (Lawrence Berkeley National Laboratory) who has all required IRB approvals to distribute these samples. Cells were grown in M87A medium with cholera toxin and oxytocin at 0.5 ng/ml and 0.1nM, respectively. 4th passage HMECs were stained with anti-human CD133-PE (Biolegend, clone 7) and anti-human CD271 (Biolegend, clone ME20.4) by following standard flow cytometry protocol. LEps and MEps were enriched using Aria III (Becton Dickinson) flow sorter as CD133^{+}/CD271^{-} and CD133^{-}/CD271^{+} fractions, respectively. The different HMEC strains used are described in Table S3.

WGBS

We examined the DNA methylome of primary LEps from younger (< 30y) premenopausal and older (> 55y) postmenopausal women. Genomic DNA from FACS enriched LEps were extracted using Quick-DNA Microprep kit (Zymo Research). Whole-genome bisulfite sequencing (WGBS-seq) was performed at Admera Health Biopharma Services. Genomic DNA was bisulfite converted using the Zymo EZ DNA methylation kit (Zymo Research). Library preparation was done using TruSeq DNA Methylation Kit with 75ng of bisulfite converted DNA as per manufacturer's recommendations. 150bp paired-end sequencing was performed on a single lane of Illumina Hiseq X Ten. We obtained about 38X coverage per genome to an average of 414 million paired-end reads (Table S1).

Sequencing reads were hard trimmed 8 bp from both ends using Trim Galore (https://github.com/FelixKrueger/TrimGalore) (version 0.4.5) to remove unwanted methylation bias arising from the library preparation. Adapter contamination was also removed using Trim Galore using --illumina option. Trimmed reads were aligned to the human reference genome (hg19) using Bismark (version 0.19.1) [81] with the --bowtie1 option [82]. Bismark

(deduplicate_bismark) to remove PCR duplicates. Methpipe [83] (version 3.4.3) was used to

determine the methylation status of individual CpG sites. The hg19 reference genome contains

about 56.4 million CpG loci (hg19) or 28.2 million CpG dyads. Methylation levels were calculated

for individual CpG dyads and are henceforth referred to as CpG sites.

DMR identification

DMRfinder [84] was used to identify DMRs. Briefly, CpG sites with at least 4X coverage in at least

6 out of 10 samples were determined. Genomic regions with at least 4 CpG sites within a

distance of 100 bp were identified. The maximum length of regions was set to 500 bp. Of these

regions, ones that had less than 20 reads covering them were discarded. The final set of regions

was then used to calculate differentially methylated regions with greater than 20% change (*P*-

value < 0.05) between pooled young and old samples.

Characterization of DMRs

Overlaps with genomic features were calculated using bedtools intersect [85] with masked CpG

islands from the UCSC genome browser [86] and repeats from the RepeatMasker annotation [87].

DMR overlaps with CpG islands, and repeat elements were determined using bedtools intersect

such that the overlapping region contains at least 1 CpG site.

Kernel smoothed plots were made using the BSSeq package with default smoothing parameters

and CpG sites with greater than 3X coverage [88]. Heatmaps were made using the pheatmap

package [89].

Identification of variably methylated regions

Variably methylated regions were identified using the Systematic Interindividual Variation (SIV)

approach [59]. Briefly, the human genome was divided into 100 bp non-overlapping windows

containing at least 1 CpG site. About 14.4 million such windows were obtained. The coverage

and methylation values were calculated for each sample across these 100bp windows using

Methpipe. Windows were then filtered by coverage as follows to obtain informative bins:

Windows with CpG <= 2 that had a coverage of at least 10 reads and windows with CpG > 2

that had a coverage of at least 10 reads at half the number of CpG sites. We obtained about

12.9 million bins that had sufficient coverage. Next, we calculated the Pearson correlation co-

efficient for each bin with its adjacent bin. Adjacent bins that were within 100 bp of each other

and a correlation >= 0.71 were merged into correlated blocks of methylation. The average

methylation for each sample was calculated for the correlated blocks. Correlated blocks which

had an interindividual range (IR) of >= 20% and at least 4 CpG sites were defined as variable

regions. Old specific variable regions were defined as regions that had an IR of >= 20% across

the five old samples and IR_{old} -IR_{young} >= 20%. Similarly, young specific variable regions were

defined as regions that had an IR of >= 20% across the five young samples and IR_{young} -IR_{old} >=

20%. These regions were further filtered to retain those that have coverage of at least 3 CpGs

in all 10 samples. To categorize variably methylated regions into variable loss or variable gain,

the highest (old_{max}) and the lowest (old_{min}) methylation values among old samples were

compared to the methylation average in young (avg_y). The absolute values of differences in

methylation between avg_y and $old_{max,}$ old_{min} were compared. If the difference in methylation

between the avg_y and old_{min} were higher than that between avg_y and old_{max}, that region was

assigned as a variable region with methylation loss

Chromatin state predictions

ChIP-seq data for mammary epithelial populations were downloaded using the International

Human Epigenome Consortium data portal (https://epigenomesportal.ca/ihec/). Bigwig files

containing ChIP-seq signal for six different histone modifications in three cell types (sample IDs:

CEMT0154, CEMT0155, and CEMT0156) were used (**Figure S4A-C**). ChIP-seq signals from

the bigwig files were binned into 200 bp windows. These binned signal files were then binarized

using BinarizeSignal in ChromHMM (version 1.20) [90]. The binarized files were used to run

ChromHMM LearnModel with 16 states. Functionally similar chromatin states were grouped

together to seven distinct chromatin states (**Figure S4C**). ChIP-seq data for breast cancer cell lines were downloaded from GEO (Accession number: GSE85158 [70]). Aligned bed files were used to generate binarized files using BinarizeBed with default options. The binarized data were used to run ChromHMM LearnModel with 18 states (**Figure S7B**). Functionally similar chromatin states were grouped together to nine distinct chromatin states. DMR overlaps with chromatin states were performed using bedtools intersect. In cases where a DMR overlapped more than one chromatin state, DMR was assigned to the state with a higher base overlap.

ATAC-seq and analysis

50,000 live FACS sorted young (n = 4) and old (n = 4) LEps were used for Tn5 transposition in duplicates using the Omni-ATAC method [91]. Libraries were sequenced to a depth of 40 million paired reads each on an Illumina HiSeq 2500 system. Raw sequencing reads were trimmed using Trim Galore (https://github.com/FelixKrueger/TrimGalore) (version 0.4.5) to remove adapters. Trimmed reads were aligned to the human reference genome (hg19) using bowtie [82] with the --best -k 1 -X 2000 --mm --chunkmbs 1024 parameters. Unmapped reads, mates as well as low quality reads and secondary alignments were removed using samtools. PCR duplicates were identified using Picard and removed using samtools. The reads were shifted by 4 bases on the sense strand and 5 bases on the anti-sense strand to account for Tn5 bias. Reads from technical replicates were pooled to generate pseudoreplicates. Peaks were called using MACS2 version 2.1.1.20160309 using -p 0.01 --nomodel --shift -37 --extsize 73 --SPMR --keep-dup all --call-summits as parameters. Peak calls from technical replicates and pseudo-replicates were compared using IDR to get the most conservative set of peaks for each sample.

RNA-seq analysis

Total RNA was isolated using Quick-RNA Microprep kit (Zymo Research) from FACS sorted young (n = 10) and old LEps (n = 8). Similarly, total RNA was isolated from young (n = 6) MEps. PolyA-enriched RNA was isolated and used for library preparation using the TruSeq RNA Library

Prep kit (Illumina). About 50 million single-end reads of length 51 bp were generated for all samples. Raw sequences were aligned to the hg19 reference genome using HISAT2 (version 2.1.0) [92] with the --dta parameter. Stringtie (version 1.3.4) [93] was used with default parameters to assemble transcripts using the Gencode v19 transcript annotation. Assembled transcripts from all libraries were further merged using --merge option in Stringtie. Merged transcript abundances were measured using bedtools coverage.

For the old LEp versus young LEp comparison, edgeR (v3.26.4) [94] was used to conduct differential gene expression analysis. Briefly, normalization factors were calculated using the trimmed mean of M values method (TMM) to eliminate composition biases between libraries. Genewise biological dispersion was estimated using edgeR's empirical Bayes approach. Then, we employed a generalized linear model (GLM) approach to account for the unnormalized distribution of gene counts, as well as additional factors, such as batch effects. Differentially regulated genes were identified with an absolute log2 fold change ≥ 0.5 and FDR < 0.05. Gene expression boxplots were generated using batch corrected RPKM values. Batch correction of RPKM values was done using limma package [95]. For LEp versus MEp comparison, DESeq2 [96] was used to normalize counts and identify differentially expressed genes (absolute log2 fold change ≥ 0.5 and p-value < 0.05).

RNA-seq data from normal and DCIS samples were obtained from GEO (Accession number: GSE69240 [68]). Fastq reads were quality and adapter trimmed using Trim Galore with the --paired option. Quality trimmed reads were aligned to the hg19 genome using STAR (version 2.6.0.a) [97] with --sjdbOverhang 100 --winAnchorMultimapNmax 100 --outFilterMultimapNmax 100 --outFilterMismatchNmax 3 --alignEndsType EndToEnd options. The SQuIRE pipeline [69] was used to measure gene and TE expression changes in DCIS as compared to normal tissues.

Enrichment of DMRs and variably methylated regions at TE subfamilies

The extent of overlap of DMRs and variable regions at repat subfamilies (RepeatMasker annotation) was calculated using bedtools intersect. Randomly shuffled control regions of the same length were generated 1000 times, and the expected number of overlaps calculated using bedtools intersect. Enrichment values were calculated by dividing the number of DMR overlaps (observed) with the average number of random overlaps (expected). *P* values were calculated by dividing the number of extreme values (at either tail of distribution) from random overlaps by 1000. Significantly enriched repeat subfamilies had $p < 0.05$, enrichment > 1.5-fold, and > 5 copies overlapping DMRs or variable regions.

Additional data analysis and external data

Mappability of 100bp bisulfite converted kmers for the hg19 genome generated using Bismap [98] were downloaded from the UCSC Genome Browser [86]. Begraph files were used to obtain the mappability score of individual CpGs within TEs. Motif scanning was performed using fimo [99] with JASPAR 2020 database with default parameters [44]. Motif enrichment analysis was performed using findMotifsGenome.pl in homer [100]. For each set of genomic regions, background sequences with matched GC content were selected. *P*-values for motif enrichment was calculated using the cumulative binomial distributions. The evolutionary age of TEs was calculated as described previously using the Jukes-Cantor correction [101]. Normalized methylation entropy and mean methylation were calculated on 150bp non-overlapping windows across the genome using informME [102]. Replication time for MC7 was obtained from ENCODE data (GSE34399). A-type and B-type compartment classification for MCF10A cells were downloaded from GSE66733 [64]. Normalized counts for TCGA-BRCA cancer specific ATAC-seq peaks were downloaded from the Genomic Data Commons (GDC) Portal. The clinical information and PAM50 subtypes for these samples were accessed using TCGAbiolinks [103]. Primary breast tumor WGBS data generated as part of the International Cancer Genome Consortium [66] and was obtained from European Genome-phenome Archiver after DACO

approval. Figures were made in R (version 3.5.1) using the ggplot2 package [104] and assembled

in Adobe Illustrator.

Availability of data and materials

All raw and processed sequencing data files have been deposited at NCBI's Gene Expression

Omnibus (GEO) under accession GSE153696.

Funding

This work was supported by the National Institutes of Health, grants R01DK112041,

R01CA220693 (D.E.S.); K01DK104993 (A.L.); Department of Defense/Army Breast Cancer Era

of Hope Scholar Award BC141351, and Expansion Award BC181737, Conrad N. Hilton

Foundation, and City of Hope Center for Cancer and Aging (M.A.L.); the National Cancer

Institute (NCI) Cancer Metabolism Training Program Postdoctoral Fellowship T32CA221709

(R.W.S.) and City of Hope Program in Molecular and Cellular Biology pilot award (D.E.S and

M.A.L.). The research reported in this publication included work performed in the Integrative

Genomics and Analytical Cytometry Cores supported by the National Cancer Institute of the

National Institutes of Health under award number P30CA033572. The content is solely the

responsibility of the authors and does not necessarily represent the official views of the National

Institutes of Health. The funding bodies had no role in the design of the study and collection,

analysis, and interpretation of data and in writing the manuscript.

Authors' contributions

PS, MAL and DES designed the study. PS, MM and CT performed experiments. PS, RWS, MB

and AL analyzed and interpreted the data. PS, MAL and DES prepared the manuscript. All

authors read and approved the final manuscript.

Acknowledgements

We thank other members of the Schones laboratory for helpful discussions and comments, and the continued involvement of patient advocates Susan Samson and Sandy Preto. The results shown and referenced here are based in part upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga, and the ENCODE Consortium: https://www.encodeproject.org/.

Conflict of Interest Statement

The authors declare that they have no potential conflicts of interest.

References

1. Lopez-Otin, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. The hallmarks of aging. *Cell* **153**, 1194-1217, doi:10.1016/j.cell.2013.05.039 (2013).

2. Booth, L. N. & Brunet, A. The Aging Epigenome. *Mol Cell* **62**, 728-744, doi:10.1016/j.molcel.2016.05.013 (2016).

3. Bird, A. DNA methylation patterns and epigenetic memory. *Genes Dev* **16**, 6-21, doi:10.1101/gad.947102 (2002).

4. Maegawa, S. *et al.* Widespread and tissue specific age-related DNA methylation changes in mice. *Genome Res* **20**, 332-340, doi:10.1101/gr.096826.109 (2010).

5. Horvath, S. DNA methylation age of human tissues and cell types. *Genome Biol* **14**, R115, doi:10.1186/gb-2013-14-10-r115 (2013).

6. Rakyan, V. K. *et al.* Human aging-associated DNA hypermethylation occurs preferentially at bivalent chromatin domains. *Genome Res* **20**, 434-439, doi:10.1101/gr.103101.109 (2010).

7. Heyn, H. *et al.* Distinct DNA methylomes of newborns and centenarians. *Proc Natl Acad Sci U S A* **109**, 10522-10527, doi:10.1073/pnas.1120658109 (2012).

8. Jemal, A. *et al.* Cancer statistics, 2007. *CA Cancer J Clin* **57**, 43-66, doi:10.3322/canjclin.57.1.43 (2007).

9. Jenkins, E. O. *et al.* Age-specific changes in intrinsic breast cancer subtypes: a focus on older women. *Oncologist* **19**, 1076-1083, doi:10.1634/theoncologist.2014-0184 (2014).

10. Quong, J. *et al.* Age-dependent changes in breast cancer hormone receptors and oxidant stress markers. *Breast Cancer Res Treat* **76**, 221-236, doi:10.1023/a:1020886801674 (2002).

11. Benz, C. C. Impact of aging on the biology of breast cancer. *Crit Rev Oncol Hematol* **66**, 65-74, doi:10.1016/j.critrevonc.2007.09.001 (2008).

12. Garbe, J. C. *et al.* Accumulation of multipotent progenitors with a basal differentiation bias during aging of human mammary epithelia. *Cancer Res* **72**, 3687-3701, doi:10.1158/0008-5472.CAN-12-0157 (2012).

13. Pelissier, F. A. *et al.* Age-related dysfunction in mechanotransduction impairs differentiation of human mammary epithelial progenitors. *Cell Rep* **7**, 1926-1939, doi:10.1016/j.celrep.2014.05.021 (2014).

14. Pelissier Vatter, F. A. *et al.* High-Dimensional Phenotyping Identifies Age-Emergent Cells in Human Mammary Epithelia. *Cell Rep* **23**, 1205-1219, doi:10.1016/j.celrep.2018.03.114 (2018).

15. Dos Santos, C. O., Dolzhenko, E., Hodges, E., Smith, A. D. & Hannon, G. J. An epigenetic memory of pregnancy in the mouse mammary gland. *Cell Rep* **11**, 1102-1109, doi:10.1016/j.celrep.2015.04.015 (2015).

16. Sayaman, R. W. *et al.* Epigenetic changes with age primes mammary luminal epithelia for cancer initiation. *bioRxiv*, 2021.2002.2012.430777, doi:10.1101/2021.02.12.430777 (2021).

17. Prat, A. & Perou, C. M. Mammary development meets cancer genomics. *Nat Med* **15**, 842-844, doi:10.1038/nm0809-842 (2009).

18. Miyano, M. *et al.* Age-related gene expression in luminal epithelial cells is driven by a microenvironment made from myoepithelial cells. *Aging (Albany NY)* **9**, 2026-2051, doi:10.18632/aging.101298 (2017).

19. Lee, J. K. *et al.* Age and the means of bypassing stasis influence the intrinsic subtype of immortalized human mammary epithelial cells. *Front Cell Dev Biol* **3**, 13, doi:10.3389/fcell.2015.00013 (2015).

20. Hofstatter, E. W. *et al.* Increased epigenetic age in normal breast tissue from luminal breast cancer patients. *Clin Epigenetics* **10**, 112, doi:10.1186/s13148-018-0534-8 (2018).

21. Castle, J. R. *et al.* Estimating breast tissue-specific DNA methylation age using next-generation sequencing data. *Clin Epigenetics* **12**, 45, doi:10.1186/s13148-020-00834-4 (2020).

22   Cordaux, R. & Batzer, M. A. The impact of retrotransposons on human genome evolution. *Nat*
Rev Genet **10**, 691-703, doi:10.1038/nrg2640 (2009).

23   Bourque, G. *et al.* Ten things you should know about transposable elements. *Genome Biol* **19**,
199, doi:10.1186/s13059-018-1577-z (2018).

24   Sundaram, V. *et al.* Widespread contribution of transposable elements to the innovation of gene
regulatory networks. *Genome Res* **24**, 1963-1976, doi:10.1101/gr.168872.113 (2014).

25   Burns, K. H. Transposable elements in cancer. *Nat Rev Cancer* **17**, 415-424,
doi:10.1038/nrc.2017.35 (2017).

26   Ishak, C. A. & De Carvalho, D. D. Reactivation of Endogenous Retroelements in Cancer
Development and Therapy. *Annual Review of Cancer Biology* **4**.

27   De Cecco, M. *et al.* Transposable elements become active and mobile in the genomes of aging
mammalian somatic tissues. *Aging (Albany NY)* **5**, 867-883, doi:10.18632/aging.100621 (2013).

28   Benayoun, B. A. *et al.* Remodeling of epigenome and transcriptome landscapes with aging in
mice reveals widespread induction of inflammatory responses. *Genome Res* **29**, 697-709,
doi:10.1101/gr.240093.118 (2019).

29   De Cecco, M. *et al.* L1 drives IFN in senescent cells and promotes age-associated inflammation.
Nature **566**, 73-78, doi:10.1038/s41586-018-0784-9 (2019).

30   Ciccarone, F. *et al.* Age-dependent expression of DNMT1 and DNMT3B in PBMCs from a large
European population enrolled in the MARK-AGE study. *Aging Cell* **15**, 755-765,
doi:10.1111/acel.12485 (2016).

31   Beerman, I. *et al.* Proliferation-dependent alterations of the DNA methylation landscape underlie
hematopoietic stem cell aging. *Cell Stem Cell* **12**, 413-425, doi:10.1016/j.stem.2013.01.017
(2013).

32   Sun, D. *et al.* Epigenomic profiling of young and aged HSCs reveals concerted changes during
aging that reinforce self-renewal. *Cell Stem Cell* **14**, 673-688, doi:10.1016/j.stem.2014.03.002
(2014).

33   Teschendorff, A. E. *et al.* Age-dependent DNA methylation of genes that are suppressed in stem
cells is a hallmark of cancer. *Genome Res* **20**, 440-446, doi:10.1101/gr.103606.109 (2010).

34   Jung, M. & Pfeifer, G. P. Aging and DNA methylation. *BMC Biol* **13**, 7, doi:10.1186/s12915-
015-0118-4 (2015).

35   Pal, B. *et al.* Global changes in the mammary epigenome are induced by hormonal cues and
coordinated by Ezh2. *Cell Rep* **3**, 411-426, doi:10.1016/j.celrep.2012.12.020 (2013).

36   Michalak, E. M. *et al.* Polycomb group gene Ezh2 regulates mammary gland morphogenesis and
maintains the luminal progenitor pool. *Stem Cells* **31**, 1910-1920, doi:10.1002/stem.1437 (2013).

37   Xie, M. *et al.* DNA hypomethylation within specific transposable element families associates
with tissue-specific enhancer landscape. *Nat Genet* **45**, 836-841, doi:10.1038/ng.2649 (2013).

38   Pehrsson, E. C., Choudhary, M. N. K., Sundaram, V. & Wang, T. The epigenomic landscape of
transposable elements across normal human development and anatomy. *Nat Commun* **10**, 5640,
doi:10.1038/s41467-019-13555-x (2019).

39   Lu, X. *et al.* The retrovirus HERVH is a long noncoding RNA required for human embryonic
stem cell identity. *Nat Struct Mol Biol* **21**, 423-425, doi:10.1038/nsmb.2799 (2014).

40   Zhang, B. *et al.* Comparative DNA methylome analysis of endometrial carcinoma reveals
complex and distinct deregulation of cancer promoters and enhancers. *BMC Genomics* **15**, 868,
doi:10.1186/1471-2164-15-868 (2014).

41   Leung, D. *et al.* Integrative analysis of haplotype-resolved epigenomes across human tissues.
Nature **518**, 350-354, doi:10.1038/nature14217 (2015).

42   Swanson, E. C., Manning, B., Zhang, H. & Lawrence, J. B. Higher-order unfolding of satellite
heterochromatin is a consistent and early event in cell senescence. *J Cell Biol* **203**, 929-942,
doi:10.1083/jcb.201306073 (2013).

43 Nakagome, Y., Abe, T., Misawa, S., Takeshita, T. & Iinuma, K. The "loss" of centromeres from
chromosomes of aged women. *Am J Hum Genet* **36**, 398-404 (1984).
44 Fornes, O. *et al.* JASPAR 2020: update of the open-access database of transcription factor
binding profiles. *Nucleic Acids Res* **48**, D87-D92, doi:10.1093/nar/gkz1001 (2020).
45 Pellacani, D. *et al.* Analysis of Normal Human Mammary Epigenomes Reveals Cell-Specific
Active Enhancer States and Associated Transcription Factor Networks. *Cell Rep* **17**, 2060-2074,
doi:10.1016/j.celrep.2016.10.058 (2016).
46 Badouel, C., Garg, A. & McNeill, H. Herding Hippos: regulating growth in flies and man. *Curr*
Opin Cell Biol **21**, 837-843, doi:10.1016/j.ceb.2009.09.010 (2009).
47 Zemojtel, T., Kielbasa, S. M., Arndt, P. F., Chung, H. R. & Vingron, M. Methylation and
deamination of CpGs generate p53-binding sites on a genomic scale. *Trends Genet* **25**, 63-66,
doi:10.1016/j.tig.2008.11.005 (2009).
48 Wang, T. *et al.* Species-specific endogenous retroviruses shape the transcriptional network of the
human tumor suppressor protein p53. *Proc Natl Acad Sci U S A* **104**, 18613-18618,
doi:10.1073/pnas.0703637104 (2007).
49 Tiwari, B. *et al.* p53 directly represses human LINE1 transposons. *Genes Dev* **34**, 1439-1451,
doi:10.1101/gad.343186.120 (2020).
50 Stadler, M. B. *et al.* DNA-binding factors shape the mouse methylome at distal regulatory
regions. *Nature* **480**, 490-495, doi:10.1038/nature10716 (2011).
51 Lister, R. *et al.* Human DNA methylomes at base resolution show widespread epigenomic
differences. *Nature* **462**, 315-322, doi:10.1038/nature08514 (2009).
52 de la Rica, L. *et al.* TET-dependent regulation of retrotransposable elements in mouse embryonic
stem cells. *Genome Biol* **17**, 234, doi:10.1186/s13059-016-1096-8 (2016).
53 Lim, E. *et al.* Aberrant luminal progenitors as the candidate target population for basal tumor
development in BRCA1 mutation carriers. *Nat Med* **15**, 907-913, doi:10.1038/nm.2000 (2009).
54 Hernando-Herraez, I. *et al.* Ageing affects DNA methylation drift and transcriptional cell-to-cell
variability in mouse muscle stem cells. *Nat Commun* **10**, 4361, doi:10.1038/s41467-019-12293-4
(2019).
55 Bahar, R. *et al.* Increased cell-to-cell variation in gene expression in ageing mouse heart. *Nature*
441, 1011-1014, doi:10.1038/nature04844 (2006).
56 Cheung, P. *et al.* Single-Cell Chromatin Modification Profiling Reveals Increased Epigenetic
Variations with Aging. *Cell* **173**, 1385-1397 e1314, doi:10.1016/j.cell.2018.03.079 (2018).
57 Martinez-Jimenez, C. P. *et al.* Aging increases cell-to-cell transcriptional variability upon
immune stimulation. *Science* **355**, 1433-1436, doi:10.1126/science.aah4115 (2017).
58 Ohtani, H., Liu, M., Zhou, W., Liang, G. & Jones, P. A. Switching roles for DNA and histone
methylation depend on evolutionary ages of human endogenous retroviruses. *Genome Res* **28**,
1147-1157, doi:10.1101/gr.234229.118 (2018).
59 Gunasekara, C. J. *et al.* A genomic atlas of systemic interindividual epigenetic variation in
humans. *Genome Biol* **20**, 105, doi:10.1186/s13059-019-1708-1 (2019).
60 Burns, K. H. & Boeke, J. D. Human transposon tectonics. *Cell* **149**, 740-752,
doi:10.1016/j.cell.2012.04.019 (2012).
61 Issa, J. P. Aging and epigenetic drift: a vicious cycle. *J Clin Invest* **124**, 24-29,
doi:10.1172/JCI69735 (2014).
62 Zhou, W. *et al.* DNA methylation loss in late-replicating domains is linked to mitotic cell
division. *Nat Genet* **50**, 591-602, doi:10.1038/s41588-018-0073-4 (2018).
63 Du, Q. *et al.* Replication timing and epigenome remodelling are associated with the nature of
chromosomal rearrangements in cancer. *Nat Commun* **10**, 416, doi:10.1038/s41467-019-08302-1
(2019).

64   Barutcu, A. R. *et al.* Chromatin interaction analysis reveals changes in small chromosome and
telomere clustering between epithelial and breast cancer cells. *Genome Biol* **16**, 214,
doi:10.1186/s13059-015-0768-0 (2015).
65   Jenkinson, G., Pujadas, E., Goutsias, J. & Feinberg, A. P. Potential energy landscapes identify
the information-theoretic nature of the epigenome. *Nat Genet* **49**, 719-729, doi:10.1038/ng.3811
(2017).
66   Brinkman, A. B. *et al.* Partially methylated domains are hypervariable in breast cancer and fuel
widespread CpG island hypermethylation. *Nat Commun* **10**, 1749, doi:10.1038/s41467-019-
09828-0 (2019).
67   Jang, H. S. *et al.* Transposable elements drive widespread expression of oncogenes in human
cancers. *Nat Genet* **51**, 611-617, doi:10.1038/s41588-019-0373-3 (2019).
68   Abba, M. C. *et al.* A Molecular Portrait of High-Grade Ductal Carcinoma In Situ. *Cancer Res*
75, 3980-3990, doi:10.1158/0008-5472.CAN-15-0506 (2015).
69   Yang, W. R., Ardeljan, D., Pacyna, C. N., Payer, L. M. & Burns, K. H. SQuIRE reveals locus-
specific regulation of interspersed repeat expression. *Nucleic Acids Res* **47**, e27,
doi:10.1093/nar/gky1301 (2019).
70   Franco, H. L. *et al.* Enhancer transcription reveals subtype-specific gene expression programs
controlling breast cancer pathogenesis. *Genome Res* **28**, 159-170, doi:10.1101/gr.226019.117
(2018).
71   Bell, C. G. *et al.* DNA methylation aging clocks: challenges and recommendations. *Genome Biol*
20, 249, doi:10.1186/s13059-019-1824-y (2019).
72   Kimmel, J. C. *et al.* Murine single-cell RNA-seq reveals cell-identity- and tissue-specific
trajectories of aging. *Genome Res* **29**, 2088-2103, doi:10.1101/gr.253880.119 (2019).
73   Rimmele, P. *et al.* Aging-like phenotype and defective lineage specification in SIRT1-deleted
hematopoietic stem and progenitor cells. *Stem Cell Reports* **3**, 44-59,
doi:10.1016/j.stemcr.2014.04.015 (2014).
74   Vandiver, A. R. *et al.* Age and sun exposure-related widespread genomic blocks of
hypomethylation in nonmalignant skin. *Genome Biol* **16**, 80, doi:10.1186/s13059-015-0644-y
(2015).
75   Cole, J. J. *et al.* Diverse interventions that extend mouse lifespan suppress shared age-associated
epigenetic changes at critical gene regulatory regions. *Genome Biol* **18**, 58, doi:10.1186/s13059-
017-1185-3 (2017).
76   Meeker, A. K. *et al.* Telomere shortening occurs in subsets of normal breast epithelium as well
as in situ and invasive carcinoma. *Am J Pathol* **164**, 925-935, doi:10.1016/S0002-
9440(10)63180-X (2004).
77   Sputova, K. *et al.* Aging phenotypes in cultured normal human mammary epithelial cells are
correlated with decreased telomerase activity independent of telomere length. *Genome Integr* **4**,
4, doi:10.1186/2041-9414-4-4 (2013).
78   Rodic, N. *et al.* Long interspersed element-1 protein expression is a hallmark of many human
cancers. *Am J Pathol* **184**, 1280-1286, doi:10.1016/j.ajpath.2014.01.007 (2014).
79   Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic
properties of tumors associated with local immune cytolytic activity. *Cell* **160**, 48-61,
doi:10.1016/j.cell.2014.12.033 (2015).
80   Labarge, M. A., Garbe, J. C. & Stampfer, M. R. Processing of human reduction mammoplasty
and mastectomy tissues for cell culture. *J Vis Exp*, doi:10.3791/50011 (2013).
81   Krueger, F. & Andrews, S. R. Bismark: a flexible aligner and methylation caller for Bisulfite-
Seq applications. *Bioinformatics* **27**, 1571-1572, doi:10.1093/bioinformatics/btr167 (2011).

82 Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient alignment
of short DNA sequences to the human genome. *Genome Biol* **10**, R25, doi:10.1186/gb-2009-10-
3-r25 (2009).
83 Song, Q. *et al.* A reference methylome database and analysis pipeline to facilitate integrative and
comparative epigenomics. *PLoS One* **8**, e81148, doi:10.1371/journal.pone.0081148 (2013).
84 Gaspar, J. M. & Hart, R. P. DMRfinder: efficiently identifying differentially methylated regions
from MethylC-seq data. *BMC Bioinformatics* **18**, 528, doi:10.1186/s12859-017-1909-0 (2017).
85 Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic
features. *Bioinformatics* **26**, 841-842, doi:10.1093/bioinformatics/btq033 (2010).
86 Kent, W. J. *et al.* The human genome browser at UCSC. *Genome Res* **12**, 996-1006,
doi:10.1101/gr.229102 (2002).
87 Smit, A., Hubley, R & Green, P. . RepeatMasker Open-4.0. http://www.repeatmasker.org.
(2013-2015).
88 Hansen, K. D., Langmead, B. & Irizarry, R. A. BSmooth: from whole genome bisulfite
sequencing reads to differentially methylated regions. *Genome Biol* **13**, R83, doi:10.1186/gb-
2012-13-10-r83 (2012).
89 Kolde, R.   (2018).
90 Ernst, J. & Kellis, M. Chromatin-state discovery and genome annotation with ChromHMM. *Nat
Protoc* **12**, 2478-2492, doi:10.1038/nprot.2017.124 (2017).
91 Corces, M. R. *et al.* An improved ATAC-seq protocol reduces background and enables
interrogation of frozen tissues. *Nat Methods* **14**, 959-962, doi:10.1038/nmeth.4396 (2017).
92 Kim, D., Langmead, B. & Salzberg, S. L. HISAT: a fast spliced aligner with low memory
requirements. *Nat Methods* **12**, 357-360, doi:10.1038/nmeth.3317 (2015).
93 Pertea, M. *et al.* StringTie enables improved reconstruction of a transcriptome from RNA-seq
reads. *Nat Biotechnol* **33**, 290-295, doi:10.1038/nbt.3122 (2015).
94 Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for
differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139-140,
doi:10.1093/bioinformatics/btp616 (2010).
95 Ritchie, M. E. *et al.* limma powers differential expression analyses for RNA-sequencing and
microarray studies. *Nucleic Acids Res* **43**, e47, doi:10.1093/nar/gkv007 (2015).
96 Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for
RNA-seq data with DESeq2. *Genome Biol* **15**, 550, doi:10.1186/s13059-014-0550-8 (2014).
97 Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15-21,
doi:10.1093/bioinformatics/bts635 (2013).
98 Karimzadeh, M., Ernst, C., Kundaje, A. & Hoffman, M. M. Umap and Bismap: quantifying
genome and methylome mappability. *Nucleic Acids Res* **46**, e120, doi:10.1093/nar/gky677
(2018).
99 Grant, C. E., Bailey, T. L. & Noble, W. S. FIMO: scanning for occurrences of a given motif.
Bioinformatics **27**, 1017-1018, doi:10.1093/bioinformatics/btr064 (2011).
100 Heinz, S. *et al.* Simple combinations of lineage-determining transcription factors prime cis-
regulatory elements required for macrophage and B cell identities. *Mol Cell* **38**, 576-589,
doi:10.1016/j.molcel.2010.05.004 (2010).
101 Bourque, G. *et al.* Evolution of the mammalian transcription factor binding repertoire via
transposable elements. *Genome Res* **18**, 1752-1762, doi:10.1101/gr.080663.108 (2008).
102 Jenkinson, G., Abante, J., Feinberg, A. P. & Goutsias, J. An information-theoretic approach to
the modeling and analysis of whole-genome bisulfite sequencing data. *BMC Bioinformatics* **19**,
87, doi:10.1186/s12859-018-2086-5 (2018).
103 Colaprico, A. *et al.* TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA
data. *Nucleic Acids Res* **44**, e71, doi:10.1093/nar/gkv1507 (2016).

104   Wickham, H. *ggplot2: elegant graphics for data analysis*. (Springer, 2016).
912

Figure Legends

Figure 1: Luminal cells from old individuals show DNA methylation changes at distinct genomic loci. (A) Methylation levels of identified DMRs across all samples. Samples are in rows, and DMRs are in columns. The color intensity represents the Z-score scaled from the mean. Values ranging from higher to lower methylation are shown as purple to green. (B) Kernel smoothed line plots of representative DMRs±500bp with methylation gain (left panel) and methylation loss (right panel). Blue and red lines respectively represent young and old samples. DMRs are highlighted in pink and black ticks mark each CpG position. (C) TE subfamilies enriched in DMRs with methylation loss. Left panel shows number of elements from each subfamily that lose methylation. Right panel shows the observed/expected ratio for each TE subfamily. Expected number of overlaps in a background set of regions with matched length and CpG density was used to calculate the ratio. (D) Genome browser tracks showing a representative example of a HERVH-int element losing methylation in old samples. Bottom tracks are from ATAC-seq data showing gain of accessibility at the DMR.

Figure 2: Transposable elements contribute to aging induced DNA methylation changes at regulatory regions. (A) Top ten TF binding sites enriched in the DMRs that lose methylation with age are shown. Dots in the left panel show -log10(p-value) for the enrichment of the transcription factor binding site. Dots in the right panel show expression levels (RPKM) of the respective transcription factor in young myoepithelial (MEp) and luminal (LEp) cells. (B) Same as A, but showing motifs enriched in DMRs overlapping transposable elements. Only the portion overlapping a TE was used for motif enrichment analysis. (C) Boxplot showing expression levels of myoepithelial-specific TF TP63 in young and old LEps (n=8, *p*-value < 0.01; two-tailed unpaired t test with Welch's correction). (D) Top ten TF binding sites enriched in the DMRs that gain methylation with age are shown. Dots in the left panel show -log10(p-value) for the enrichment of the TF binding site. Dots in the right panel show expression levels (RPKM) of the respective transcription factor in young myoepithelial (MEp) and luminal (LEp) cells. (E) Same as D, but showing motifs enriched in DMRs overlapping transposable elements. Only the portion

overlapping TEs was used for motif enrichment analysis. (F) Boxplot showing expression levels of luminal lineage-specific TF ELF5 in young and old LEps (n=8, *p*-value < 0.05; two-tailed Mann Whitney test). (G) Schematic showing the role of myoepithelial-specific transcription factors in causing loss of methylation. Conversely, loss of expression of luminal-specific transcription factors leads to unbound sites being methylated, leading to methylation gain. (H) Enrichment of TF binding site in each TE subfamily with methylation loss. Color scale is –log10(p-value) of TF motif enrichment.

Figure 3: Variably methylated regions with methylation loss are enriched at young transposable elements (A-D) Evolutionary age of (A) all TE elements (B) SINE, (C) LINE, and (D) LTR/ERV elements that are variably methylated with methylation loss or gain. Evolutionary ages of only the significantly enriched TE subfamilies are plotted. (E) TE subfamilies enriched in DMRs with methylation loss. Left-right; panels show evolutionary age, CpG density, number of elements from each subfamily that lose methylation and the observed/expected ratio for each TE subfamily. Expected number of overlaps in shuffled controls was used to calculate the ratio. In the evolutionary age and CpG density panels, brown points indicate the median. (F) Genome browser tracks showing a representative example of a HERVH-int element showing variable methylation loss in old samples. Bottom tracks are from ATAC-seq data showing gain of accessibility at the variably methylated region in the corresponding sample.

Figure 4: Stochastic methylation loss at transposons associated with heterochromatin regions. **(**A, C) Density plots showing replication time of (A) all variably methylated regions and (C) variably methylated TEs in young and old using MCF7 Repli-Seq data. Vertical dashed lines indicate late (weighted average < 17) or early (weighted average < 73) cutoffs. (B) Proportion of variably methylated regions in young and old samples that are at late or early replicating region. (D) Same as B but showing proportion of variably methylated TEs. For B and D, asterisks indicate enrichment (p-value < 0.0001, Fisher's exact test) (E) Percent of variable regions in old and young cells (top panel) that are in A or B type compartments in mammary epithelial cells. Bottom panel shows percent of variable TEs in old and young cells that are in A or B type compartments. Published MCF10A HiC data was used for A and B-

type prediction. Asterisks indicate enrichment (p-value < 0.0001, Fisher's exact test) (F) Plots showing methylation entropy, a measure of methylation heterogeneity at variably methylated regions and (G) variably methylated TEs in A and B-type compartments. F and G. *p*-values were calculated using Kolmogorov-Smirnov (KS) test for equality of distributions. (H) Scatterplots of DNA methylation and entropy levels of variably methylated HERVH and (I) MER52A elements that lose methylation. Marginal density plots are shown to display the density of points on the X and Y axes.

Figure 5: Transposable elements with age-dependent methylation loss are activated in breast cancer. (A) Frequency of overlap with partially methylated domains at variably methylated TEs among 30 primary breast cancer samples. (B) A representative HERVH element showing variable loss of methylation in old samples and in breast cancer (BC) samples. BC WGBS tracks are shown in the dense mode to save space. Methylation loss is evident from grey bars instead of black (fully methylated). PAM50 subtypes and estrogen receptor (ER) expression status of the tumors are shown for the BC WGBS tracks. Bottom tracks are RNA-seq tracks from DCIS samples showing cryptic transcription of the HERVH element. All RNA-seq tracks are scaled to the same value and PAM50 subtype is indicated on the right. (C) Heatmap showing signals across 74 TCGA-BRCA samples for ATAC-seq peaks that overlap TEs hypomethylated with age. (D) Heatmaps showing chromatin states identified at hypomethylated L1PA2 elements in normal cells, transformed mammary cell lines and breast cancer cell lines. Each column shows a hypomethylated L1PA2 element in aging LEps. (E) Genome browser tracks showing methylation loss at a HERVH element near the *CYB5A* gene promoter. (F) Expression of *CYB5A* in normal and ductal carcinoma in situ (DCIS) samples (p-value < 0.001; two-tailed unpaired t test with Welch's correction) and (G) in five subtypes of breast tumors from the TCGA BRCA collection (p-value Luminal A (LumA) versus Basal and Luminal B (LumB) versus Basal (p-value < 2.2x10-16; using two-tailed Wilcoxon signed-rank test).

Figures

Figure 1: Luminal cells from old individuals show DNA methylation changes at distinct genomic loci. (A) Methylation levels of identified DMRs across all samples. Samples are in rows, and DMRs are in columns. The color intensity represents the Z-score scaled from the mean. Values ranging from higher to lower methylation are shown as purple to green. (B) Kernel smoothed line plots of representative DMRs±500bp with methylation gain (left panel) and methylation loss (right panel). Blue and red lines respectively represent young and old samples. DMRs are highlighted in pink and black ticks mark each CpG position. (C) TE subfamilies enriched in DMRs with methylation loss. Left panel shows number of elements from each subfamily that lose methylation. Right panel shows the observed/expected ratio for each TE subfamily. Expected number of overlaps in a background set of regions with matched length and CpG density was used to calculate the ratio. (D) Genome browser tracks showing a representative example of a HERVH-int element losing methylation in old samples. Bottom tracks are from ATAC-seq data showing gain of accessibility at the DMR.

Figure 2: Transposable elements contribute to aging induced DNA methylation changes at regulatory regions. (A) Top ten TF binding sites enriched in the DMRs that lose methylation with age are shown. Dots in the left panel show -log10(p-value) for the enrichment of the transcription factor binding site. Dots in the right panel show expression levels (RPKM) of the respective transcription factor in young myoepithelial (MEp) and luminal (LEp) cells. (B) Same as A, but showing motifs enriched in DMRs overlapping transposable elements. Only the portion overlapping a TE was used for motif enrichment analysis. (C) Boxplot showing expression levels of myoepithelial-specific TF TP63 in young and old LEps (n=8, p-value < 0.01; two-tailed unpaired t test with Welch's correction). (D) Top ten TF binding sites enriched in the DMRs that gain methylation with age are shown. Dots in the left panel show -log10(p-value) for the enrichment of the TF binding site. Dots in the right panel show expression levels (RPKM) of the respective transcription factor in young myoepithelial (MEp) and luminal (LEp) cells. (E) Same as D, but showing motifs enriched in DMRs overlapping transposable elements. Only the portion overlapping TEs was used for motif enrichment analysis. (F) Boxplot showing expression levels of luminal lineage-specific TF ELF5 in young and old LEps (n=8, p-value < 0.05; two-tailed Mann Whitney test). (G) Schematic showing the role of myoepithelial-specific transcription factors in causing loss of methylation. Conversely, loss of expression of luminal-specific transcription factors leads to unbound sites being methylated, leading to methylation gain. (H) Enrichment of TF binding site in each TE subfamily with methylation loss. Color scale is –log10(p-value) of TF motif enrichment.

Figure 3: Variably methylated regions with methylation loss are enriched at young transposable elements (A-D) Evolutionary age of (A) all TE elements (B) SINE, (C) LINE, and (D) LTR/ERV elements that are variably methylated with methylation loss or gain. Evolutionary ages of only the significantly enriched TE subfamilies are plotted. (E) TE subfamilies enriched in DMRs with methylation loss. Left-right; panels show evolutionary age, CpG density, number of elements from each subfamily that lose methylation and the observed/expected ratio for each TE subfamily. Expected number of overlaps in shuffled controls was used to calculate the ratio. In the evolutionary age and CpG density panels, brown points indicate the median. (F) Genome browser tracks showing a representative example of a HERVH-int element showing variable methylation loss in old samples. Bottom tracks are from ATAC-seq data showing gain of accessibility at the variably methylated region in the corresponding sample.

Figure 4: Stochastic methylation loss at transposons associated with heterochromatin regions. (A, C) Density plots showing replication time of (A) all variably methylated regions and (C) variably methylated TEs in young and old using MCF7 Repli-Seq data. Vertical dashed lines indicate late (weighted average < 17) or early (weighted average < 73) cutoffs. (B) Proportion of variably methylated regions in young and old samples that are at late or early replicating region. (D) Same as B but showing proportion of variably methylated TEs. For B and D, asterisks indicate enrichment (p-value < 0.0001, Fisher's exact test) (E) Percent of variable regions in old and young cells (top panel) that are in A or B

type compartments in mammary epithelial cells. Bottom panel shows percent of variable TEs in old and young cells that are in A or B type compartments. Published MCF10A HiC data was used for A and B-type prediction. Asterisks indicate enrichment (p-value < 0.0001, Fisher's exact test) (F) Plots showing methylation entropy, a measure of methylation heterogeneity at variably methylated regions and (G) variably methylated TEs in A and B-type compartments. F and G. *p*-values were calculated using Kolmogorov-Smirnov (KS) test for equality of distributions. (H) Scatterplots of DNA methylation and entropy levels of variably methylated HERVH and (I) MER52A elements that lose methylation. Marginal density plots are shown to display the density of points on the X and Y axes.

Figure 5: Transposable elements with age-dependent methylation loss are activated in breast cancer. (A) Frequency of overlap with partially methylated domains at variably methylated TEs among 30 primary breast cancer samples. (B) A representative HERVH element showing variable loss of methylation in old samples and in breast cancer (BC) samples. BC WGBS tracks are shown in the dense mode to save space. Methylation loss is evident from grey bars instead of black (fully methylated). PAM50 subtypes and estrogen receptor (ER) expression status of the tumors are shown for the BC WGBS tracks. Bottom tracks are RNA-seq tracks from DCIS samples showing cryptic transcription of the HERVH element. All RNA-seq tracks are scaled to the same value and PAM50 subtype is indicated on the right. (C) Heatmap showing signals across 74 TCGA-BRCA samples for ATAC-seq peaks that overlap TEs hypomethylated with age. (D) Heatmaps showing chromatin states identified at hypomethylated L1PA2 elements in normal cells, transformed mammary cell lines and breast cancer cell lines. Each column shows a hypomethylated L1PA2 element in aging LEps. (E) Genome browser tracks showing methylation loss at a HERVH element near the *CYB5A* gene promoter. (F) Expression of *CYB5A* in normal and ductal carcinoma in situ (DCIS) samples (p-value < 0.001; two-tailed unpaired t test with Welch's correction) and (G) in five subtypes of breast tumors from the TCGA BRCA collection (p-value Luminal A (LumA) versus Basal and Luminal B (LumB) versus Basal (p-value < 2.2x10-16; using two-tailed Wilcoxon signed-rank test).